Lab
Eurofins Diatherix Laboratories LLC
Eurofins Diatherix Laboratories LLC was paid $145.14M by Medicaid between Jan 2018 and Dec 2024, across 35 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 36% of everything it billed.
33Billing provider infoEUROFINS DIATHERIX LABORATORIES LLC
HUNTSVILLE, AL 35806
HUNTSVILLE, AL 35806
33aNPI1134377781assigned 09/08/2008
33bProvider typeClinical Medical Laboratory
28Total paid$145.14M
24GClaims4,714,639
24DCodes billed35
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Alabama
Rank by total paid#3 of 61
Median peer was paid$46K
This provider vs. median3,187×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 392,049 | $14.05M | |
| 2019 | 447,051 | $16.74M | |
| 2020 | 719,608 | $28.03M | |
| 2021 | 1,086,924 | $34.63M | |
| 2022 | 1,042,876 | $26.79M | |
| 2023 | 645,646 | $15.54M | |
| 2024incomplete | 380,485 | $9.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 36% | 535,387 | 438,344 | $51.96M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 23% | 595,953 | 486,819 | $33.41M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 6.7% | 588,109 | 303,996 | $9.67M |
| 87581 | 5.9% | 548,173 | 447,673 | $8.61M | |
| 87507 | 4.7% | 65,787 | 59,890 | $6.75M | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4.4% | 484,167 | 391,939 | $6.44M |
| 87631 | 2.7% | 97,610 | 84,816 | $3.92M | |
| 87486 | 2.6% | 196,560 | 163,990 | $3.84M | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.2% | 290,994 | 246,769 | $3.16M |
| 87481 | 2.1% | 162,150 | 70,459 | $3.05M | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 194,075 | 170,988 | $2.46M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.7% | 195,812 | 172,531 | $2.42M |
23 more codes
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.4% | 187,167 | $2.09M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 65,941 | $1.62M |
| 87511 | <1% | 145,471 | $1.45M | |
| 87529 | <1% | 103,316 | $1.15M | |
| 87641 | <1% | 96,612 | $1.05M | |
| 87541 | <1% | 84,164 | $984K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,516 | $246K |
| 87500 | <1% | 19,307 | $240K | |
| 87632 | <1% | 4,614 | $189K | |
| 87563 | <1% | 16,044 | $132K | |
| 87505 | <1% | 3,447 | $82K | |
| 87634 | <1% | 8,081 | $68K | |
| 87501 | <1% | 6,956 | $63K | |
| 87498 | <1% | 3,603 | $38K | |
| 87532 | <1% | 1,319 | $13K | |
| 87799 | <1% | 324 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,043 | $10K |
| 87653 | <1% | 978 | $8K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 274 | $4K |
| 87493 | <1% | 210 | $3K | |
| 87186 | <1% | 718 | $2K | |
| 87088 | <1% | 718 | $2K | |
| 99499 | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBEVERLY, KRISTIN (CONTRACT PAYOR SPECIALIST)